


REBALANCE

the EQUATION



Is replacement the only option?

Hemophilia has always been thought of as missing something. Adding or replacing clotting factor, also known as replacement therapy, has been the go-to approach for correcting this imbalance.



But what if we thought about it differently?

What if needs in hemophilia focused on the other side of the scale? Years of research have led to another investigational approach to restoring hemostasis...**rebalancing**.

Hemostasis: How the body prevents or stops bleeding


The hemostatic equation.

Think of your body's clotting cascade as a scale evenly balanced between 2 sides—one with **procoagulants** and the other with **anticoagulants**.


Factor VIII and **factor IX** are considered procoagulants because they promote clotting.

TFPI (tissue factor pathway inhibitor), **APC** (activated protein C), and **AT** (antithrombin) are examples of anticoagulants, which promote blood flow.


When procoagulant and anticoagulant sides are balanced, they achieve **hemostasis**.



In people with hemophilia A or B, factor is limited, so the balance is off and anticoagulants tip the scale toward bleeds.



Hemostasis can be achieved either through replacing the missing procoagulant or removing an anticoagulant, seen here.



Rebalancing is currently being researched to address multiple needs in hemophilia.



What is “rebalancing”?

Replacement therapies add procoagulants to reach hemostasis. However, the **rebalancing approach** reduces anticoagulants.

Anticoagulants that can be targeted include **TFPI, APC,** and **antithrombin.** These proteins already naturally occur in the body.

Studies suggest that **TFPI inhibition**, a new rebalancing approach, may be able to restore hemostasis. TFPI limits several different clotting factors’ ability to create thrombin, so it plays a key role in the coagulation cascade. By inhibiting TFPI, thrombin can be produced, which may improve clotting function.

The rebalancing approach may have the potential to restore hemostasis:



Across hemophilia A and B



Regardless of inhibitor status

Explore rebalancing with your healthcare team.

The World Federation of Hemophilia (WFH) website is another valuable resource where you can learn more about rebalancing and other therapies.

Explore the [WFH Shared Decision-making Tool](#).

- Step-by-step guides
- Goal assessments
- Questions for your healthcare team



Take time to check in with yourself and work together with your healthcare team to make the best choices for you.

Your story matters, too. It's important to take time, check in, and ask questions.

Pfizer has been committed to innovation in hemophilia care for more than **25 years**.

Pfizer has a long history of supporting the hemophilia community, and we remain committed to innovation and continued research. While significant progress has been made, we believe more can be done to improve treatment.

Stay in the loop. Sign up for updates on rebalancing at [RebalancingHemophilia.com](https://www.RebalancingHemophilia.com)

